Pédiatrie Tumeurs solides
AMG 20110261
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non-central Nervous System Tumors That are Amenable to Direct Injection.
Paris
ISABELLE AERTS
Pédiatrie Tumeurs solides
MICCHADO (IC 2017-02)
Molecular and Immunological Characterisation of high risk CHildhood Cancer At DiagnOsis, treatment and follow-up - Biological evaluation in children, adolescents and young adults.
Paris
GUDRUN SCHLEIERMACHER
Pédiatrie Sarcomes
CombinaiR3
First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years
Paris
VALERIE LAURENCE
Pédiatrie Tumeurs solides
METRO-PD1-1708
Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma
Paris
ISABELLE AERTS
Pédiatrie Hématologie
EURONET-PHL-C2
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Paris
HELENE PACQUEMENT
Pédiatrie Sarcomes
SARCOME 13 (Pédiatrie)
Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)
Paris
HELENE PACQUEMENT
Pédiatrie Tumeurs solides
D419EC00001
Phase I/II, open-label, multicentre study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in paediatric patients with advanced solid tumours, haematological malignancies including lymphoma and acute leukaemias
Paris
FRANCOIS DOZ